Brain Tumor Res Treat.  2022 Oct;10(4):244-254. 10.14791/btrt.2022.0030.

Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome

• Seo DO
• Song SW
• Kim YH
• Hong CK
• Kim JH

• KMID: 2534723
• DOI: http://doi.org/10.14791/btrt.2022.0030

Abstract

Background
Anaplastic meningioma is very rare and is generally known to have a poor prognosis. However, due to its rarity, the relationship between clinical prognosis and prognostic factors is not clear. We analyzed the prognostic factors influencing survival outcomes of patients with anaplastic meningioma. Moreover, we analyzed on the progression pattern and the response to treatment about anaplastic meningioma.
Methods
Retrospective review of 48 patients with diagnosis of World Health Organization (WHO) grade 3 meningioma was performed. According to diagnosis type, primary anaplastic meningioma was included in 28 cases and secondary anaplastic meningioma in 20 cases. Gross total resection was performed in 36 patients (75.0%), and 32 patients (66.7%) received adjuvant radiotherapy after tumor resection with confirmed WHO grade 3 meningioma. Kaplan-Meier survival curve and Cox proportional hazards modeling were used for outcome analysis.
Results
The median progression-free survival (PFS) and overall survival (OS) were 13.9 months (95% confidence interval [CI], 8.8 to 19.1) and 56.9 months (95% CI, 24.1 to 89.7), respectively. Adjuvant radiotherapy was a robust prognostic factor for PFS and OS. Extent of resection and diagnosis type which appeared to be significant prognostic factors in univariate analysis were failed to prove statistical significance in multivariate analysis.
Conclusion
Adjuvant radiotherapy is an essential treatment arm in patients with anaplastic meningiomas. Stereotactic radiosurgery seems to play an important role as a salvage treatment. But chemotherapy seems to have limited efficacy. Because of the disseminated nature of the disease, further investigations to improve survival outcome are needed.

Keyword

Anaplastic meningioma; Surgery; Adjuvant radiotherapy; Prognosis; Progression

Figure

• 

  Fig. 1 Kaplan–Meier survival analysis. A and B: The 2-year and 5-year progression-free survival (PFS) rate 40.0% and 21.8%, respectively (A). The 2-year and 5-year overall survival (OS) rate 76.7% and 47.9%, respectively (B). C and D: Adjuvant radiotherapy showed statistically meaningful result in both PFS (C) and OS (D).

• 

  Fig. 2 Kaplan-Meier survival analysis of local control. A: When the tumor volume was smaller than 7 cm3, the local control rate of steretactic radiosurgery (SRS) was higher (p<0.001). B: If the time interval between diagnosis of anaplastic meningioma and SRS was shorter than 24 months, local control rate was statistically lower (p≤0.05). C: Although the marginal dose is not statistically significant, it shows a trend that is helpful for local control as it is higher.

Reference

1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019; 21(Suppl 5):v1–v100. PMID: 31675094.

2. Ogasawara C, Philbrick BD, Adamson DC. Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines. 2021; 9:319. PMID: 33801089.

3. Kim JK, Jung TY, Jung S, Lee KH, Kim SK, Lee EJ. Meningiomas with rhabdoid or papillary components: prognosis and comparison with anaplastic meningiomas. J Korean Neurosurg Soc. 2016; 59:357–362. PMID: 27446516.

4. Masalha W, Heiland DH, Delev D, Fennell JT, Franco P, Scheiwe C, et al. Survival and prognostic predictors of anaplastic meningiomas. World Neurosurg. 2019; 131:e321–e328. PMID: 31356972.

5. Palma L, Celli P, Franco C, Cervoni L, Cantore G. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg. 1997; 86:793–800. PMID: 9126894.

6. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg. 2010; 113:202–209. PMID: 20225922.

7. Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol. 1998; 37:177–188. PMID: 9524097.

8. Kang H, Song SW, Ha J, Won YJ, Park CK, Yoo H, et al. A nationwide, population-based epidemiology study of primary central nervous system tumors in Korea, 2007-2016: a comparison with United States data. Cancer Res Trea. 2021; 53:355–366.

9. Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET, et al. Management of atypical and malignant meningiomas: role of high-dose, 3D-conformal radiation therapy. J Neurooncol. 2000; 48:151–160. PMID: 11083080.

10. Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014; 16:628–636. PMID: 24696499.

11. Orton A, Frandsen J, Jensen R, Shrieve DC, Suneja G. Anaplastic meningioma: an analysis of the National Cancer Database from 2004 to 2012. J Neurosurg. 2018; 128:1684–1689. PMID: 28731397.

12. Hassoun J. [New WHO classification of central nervous system tumors]. Bull Cancer Radiother. 1994; 81:330–334. French. PMID: 7702918.

13. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000; 88:2887. PMID: 10870076.

14. Kobyakov GL, Absalyamova OV, Poddubskiy AA, Lodygina KS, Kobyakova EA. [The 2016 WHO classification of primary central nervous system tumors: a clinician's view]. Zh Vopr Neirokhir Im N N Burdenko. 2018; 82:88–96. Russian.

15. DeWitt JC, Mock A, Louis DN. The 2016 WHO classification of central nervous system tumors: what neurologists need to know. Curr Opin Neurol. 2017; 30:643–649. PMID: 28901970.

16. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23:1231–1251. PMID: 34185076.

17. Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous system: clinical implications. Neuro Oncol. 2021; 23:1215–1217. PMID: 34185090.

18. Paek SH, Kim CY, Kim YY, Park IA, Kim MS, Kim DG, et al. Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol. 2002; 60:235–245. PMID: 12510775.

19. Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer. 1999; 85:936–944. PMID: 10091773.

20. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008; 79:574–580. PMID: 17766430.

21. Zhao P, Hu M, Zhao M, Ren X, Jiang Z. Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev. 2015; 38:101–107. discussion 107. PMID: 25139398.

22. Choi Y, Lim DH, Jo K, Nam DH, Seol HJ, Lee JI. Efficacy of postoperative radiotherapy for high grade meningiomas. J Neurooncol. 2014; 119:405–412. PMID: 24965339.

23. Moliterno J, Cope WP, Vartanian ED, Reiner AS, Kellen R, Ogilvie SQ, et al. Survival in patients treated for anaplastic meningioma. J Neurosurg. 2015; 123:23–30. PMID: 25859807.

24. McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, et al. Factors associated with survival in patients with meningioma. J Neurosurg. 1998; 88:831–839. PMID: 9576250.

25. Pollock BE, Stafford SL, Link MJ, Garces YI, Foote RL. Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas: treatment results on the basis of a 22-year experience. Cancer. 2012; 118:1048–1054. PMID: 21773968.

26. Krayenbühl N, Pravdenkova S, Al-Mefty O. De novo versus transformed atypical and anaplastic meningiomas: comparisons of clinical course, cytogenetics, cytokinetics, and outcome. Neurosurgery. 2007; 61:495–503. discussion 503-4. PMID: 17881961.

27. Cain SA, Smoll NR, Van Heerden J, Tsui A, Drummond KJ. Atypical and malignant meningiomas: considerations for treatment and efficacy of radiotherapy. J Clin Neurosci. 2015; 22:1742–1748. PMID: 26213286.

28. Hale AT, Wang L, Strother MK, Chambless LB. Differentiating meningioma grade by imaging features on magnetic resonance imaging. J Clin Neurosci. 2018; 48:71–75. PMID: 29174756.

29. Chernov MF, Kasuya H, Nakaya K, Kato K, Ono Y, Yoshida S, et al. ¹H-MRS of intracranial meningiomas: what it can add to known clinical and MRI predictors of the histopathological and biological characteristics of the tumor? Clin Neurol Neurosurg. 2011; 113:202–212. PMID: 21144647.

30. Kane AJ, Sughrue ME, Rutkowski MJ, Shangari G, Fang S, McDermott MW, et al. Anatomic location is a risk factor for atypical and malignant meningiomas. Cancer. 2011; 117:1272–1278. PMID: 21381014.

31. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP. Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci. 2010; 17:584–587. PMID: 20219376.

32. Pistolesi S, Fontanini G, Camacci T, De Ieso K, Boldrini L, Lupi G, et al. Meningioma-associated brain oedema: the role of angiogenic factors and pial blood supply. J Neurooncol. 2002; 60:159–164. PMID: 12635663.

33. Coroller TP, Bi WL, Huynh E, Abedalthagafi M, Aizer AA, Greenwald NF, et al. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12:e0187908. PMID: 29145421.

34. Liu Y, Chotai S, Chen M, Jin S, Qi ST, Pan J. Preoperative radiologic classification of convexity meningioma to predict the survival and aggressive meningioma behavior. PLoS One. 2015; 10:e0118908. PMID: 25786236.

35. Buetow MP, Buetow PC, Smirniotopoulos JG. Typical, atypical, and misleading features in meningioma. Radiographics. 1991; 11:1087–1106. PMID: 1749851.

36. Nakasu S, Nakasu Y, Nakajima M, Matsuda M, Handa J. Preoperative identification of meningiomas that are highly likely to recur. J Neurosurg. 1999; 90:455–462. PMID: 10067913.

37. Helis CA, Hughes RT, Cramer CK, Tatter SB, Laxton AW, Bourland JD, et al. Stereotactic radiosurgery for atypical and anaplastic meningiomas. World Neurosurg. 2020; 144:e53–e61. PMID: 32758657.

38. Basalamah A, Al-Bolbol M, Ahmed O, Ali N, Al-Rashed S. Stereotactic radiosurgery (SRS) induced higher-grade transformation of a benign meningioma into atypical meningioma. Case Rep Surg. 2022; 2022:4478561. PMID: 35251732.

39. Shepard MJ, Xu Z, Kearns K, Li C, Chatrath A, Sheehan K, et al. Stereotactic radiosurgery for atypical (World Health Organization II) and anaplastic (World Health Organization III) meningiomas: results from a multicenter, international cohort study. Neurosurgery. 2021; 88:980–988. PMID: 33469655.

40. Hasegawa H, Vakharia K, Link MJ, Stafford SL, Brown PD, Parney IF, et al. The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience. J Neurooncol. 2021; 155:335–342. PMID: 34705189.

41. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014; 16:829–840. PMID: 24500419.